Showing 1-30 of 63 results for "


Elisavet Paplomata et al.
Breast cancer research and treatment, 140(3), 453-462 (2013-08-03)
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR), which has been approved in combination with exemestane for hormone receptor-positive (HR) breast cancer after failure of treatment with non-steroidal aromatase inhibitors. Everolimus is generally very well...
Antonios Karanasos et al.
Journal of the American College of Cardiology, 64(22), 2343-2356 (2014-12-04)
Although recent observations suggest a favorable initial healing process of the everolimus-eluting bioresorbable vascular scaffold (BVS), little is known regarding long-term healing response. This study assessed the in vivo vascular healing response using optical coherence tomography (OCT) 5 years after...
Ivy Altomare et al.
Expert opinion on pharmacotherapy, 14(4), 505-513 (2013-02-15)
There has been a strong preclinical rationale for studying mammalian target of rapamycin (mTOR) inhibitors as single agents or in combination, in multiple malignancies and colorectal cancer in particular. The authors summarize the complete clinical experience to date of all...
Rafael A Vicens et al.
Journal of computer assisted tomography, 38(4), 574-577 (2014-06-03)
Renal epithelioid angiomyolipoma (EAML) is a perivascular epithelioid cell tumor. Although the overwhelming majority of renal EAMLs are benign, cases of aggressive behavior and malignancy have been reported. Here, we report the case of a 62-year-old woman with a 12.5-cm...
Autumn J McRee et al.
Cancer chemotherapy and pharmacology, 74(1), 117-123 (2014-05-14)
This phase I study investigated the safety, dose-limiting toxicity, and efficacy in three cohorts all treated with the mTOR inhibitor everolimus that was delivered (1) in combination with 5-fluorouracil with leucovorin (5-FU/LV), (2) with mFOLFOX6 (5-FU/LV + oxaliplatin), and (3)...
Thomas Powles et al.
European journal of cancer (Oxford, England : 1990), 50(12), 2057-2064 (2014-06-09)
Everolimus (mammalian target of rapmaycin (mTOR) inhibitor) and dovitinib (vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) inhibitor) demonstrate activity in metastatic clear cell renal cancer. The combination of these agents has a broad spectrum of relevant...
Christophe J Van Dyck et al.
Journal of interventional cardiology, 26(3), 278-286 (2013-04-24)
Compared to bare metal stent angioplasty, first-generation drug-eluting stents (DES) have markedly reduced the incidence of in-stent restenosis. However, given the increased concerns over late and very late stent thrombosis, newer-generation DES were developed. To date, these DES have virtually...
When is downstream pathway inhibition important?
Sheridan Wilson et al.
The Lancet. Oncology, 15(6), 541-542 (2014-05-09)
Hirohiko Yasui et al.
Cancer letters, 347(1), 114-122 (2014-02-05)
We examined efficacy of the mTOR inhibitor RAD001 to seek novel therapies for synovial sarcoma (SS). Although RAD001 had significant anti-tumor effects, its sensitivity differed among cell lines. Phospho-receptor tyrosine kinase (RTK) array analyses revealed c-MET phosphorylation in highly mTOR...
Shang Guo Piao et al.
Transplantation, 98(1), 22-28 (2014-05-16)
Drug-drug interaction between everolimus (EVR) and tacrolimus (TAC) is still undetermined. We evaluated whether EVR enhances TAC-induced organ injury through drug-drug interaction. Tacrolimus (6 mg/kg) was given to rats with or without EVR (1 or 2 mg/kg) orally for 4...
Thomas Pilgrim et al.
Lancet (London, England), 384(9960), 2111-2122 (2014-09-06)
Refinements in stent design affecting strut thickness, surface polymer, and drug release have improved clinical outcomes of drug-eluting stents. We aimed to compare the safety and efficacy of a novel, ultrathin strut cobalt-chromium stent releasing sirolimus from a biodegradable polymer...
James C Yao et al.
Cancer research, 73(5), 1449-1453 (2013-02-26)
The incidence of neuroendocrine tumors (NET) has increased dramatically in the past 30 years. This information has revitalized basic and clinical research into the molecular biology of NET and has resulted in the recent approval of new therapies for pancreatic...
Peyman Hadji et al.
Critical reviews in oncology/hematology, 87(2), 101-111 (2013-07-11)
Patients with breast cancer face substantial challenges to bone health from bone metastases, as well as from chemotherapy and endocrine therapies that generally elicit disease control at the cost of increased bone turnover. Consequently, maintaining bone health is of critical...
Eleonora Teplinsky et al.
Breast cancer research and treatment, 141(2), 167-172 (2013-09-05)
Hepatitis B reactivation can occur with cytotoxic chemotherapy in patients with hepatitis B and cancer. Reactivation can occur in a patient with chronic hepatitis, an inactive carrier, or one with resolved hepatitis. Clinical presentation may range from subclinical elevation of...
Michael Cardamone et al.
The Journal of pediatrics, 164(5), 1195-1200 (2014-02-13)
To evaluate the efficacy and side effects of oral mammalian target of rapamycin (mTOR) inhibitors in children and adolescents with tuberous sclerosis complex (TSC) and intractable epilepsy or subependymal giant cell astrocytoma (SEGA). Single-center series of 13 children and adolescents...
Nabil F Saba et al.
Cancer, 120(24), 3940-3951 (2014-08-12)
Platinum-based therapy combined with cetuximab is standard first-line therapy for recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Preclinical studies have suggested that mammalian target of rapamycin inhibitors may overcome resistance to epidermal growth factor receptor...
Nikhil Wagle et al.
The New England journal of medicine, 371(15), 1426-1433 (2014-10-09)
Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain undefined. Resistance developed in a patient with metastatic anaplastic thyroid carcinoma after an...
Renpei Kato et al.
Japanese journal of clinical oncology, 44(5), 479-485 (2014-04-02)
Everolimus is positioned as second-line treatment for metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitors. We investigated retrospectively the efficacy and safety of everolimus in Japanese patients with advanced renal cell carcinoma in the clinical...
Emiliano Calvo et al.
European journal of cancer (Oxford, England : 1990), 50(7), 1321-1329 (2014-03-07)
The mammalian target of rapamycin inhibitor (mTORI) everolimus and the tyrosine kinase inhibitor (TKI) axitinib are the only two post-first-line treatment options for metastatic renal cell carcinoma (mRCC) licensed at present. Extrapolation of robust phase III studies suggests that median...
Annarita Conconi et al.
British journal of haematology, 166(1), 69-76 (2014-03-29)
The International Extranodal Lymphoma Study Group coordinated a phase II trial to evaluate the activity and safety of everolimus in marginal zone lymphomas (MZLs). Thirty patients with relapsed/refractory MZLs received everolimus for six cycles or until dose-limiting toxicity or progression....
Matteo Santoni et al.
Biochimica et biophysica acta, 1845(2), 221-231 (2014-02-01)
The mammalian target of rapamycin (mTOR) has emerged as an attractive cancer therapeutic target. Treatment of metastatic renal cell carcinoma (mRCC) has improved significantly with the advent of agents targeting the mTOR pathway, such as temsirolimus and everolimus. Unfortunately, a...
Long-term favorable coronary healing after bioresorbable scaffold implantation: insights from OCT.
Nieves Gonzalo et al.
Journal of the American College of Cardiology, 64(22), 2357-2359 (2014-12-04)
News products to avoid.
Prescrire international, 23(148), 105-105 (2014-05-27)
Sohita Dhillon
Drugs, 73(5), 475-485 (2013-03-27)
Oral everolimus (Afinitor(®)) in combination with exemestane is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor (HER) 2-negative advanced breast cancer in postmenopausal women after failure of treatment with letrozole or anastrozole (in the USA) or...
Viktor Grünwald et al.
Onkologie, 36(5), 295-302 (2013-05-22)
Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), an intracellular protein kinase downstream of the phosphatidylinositol 3-kinase/AKT pathway involved in key components of tumorigenesis, including cell growth, proliferation, and angiogenesis. In the advanced cancer setting...
Chang-Kwon Oh et al.
Transplantation, 99(1), 180-186 (2014-07-02)
Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination. We examined the safety and efficacy of the use of everolimus with a cyclosporine-sparing strategy in de novo renal transplant recipients. A comparative, parallel, randomized, open-label 1-year...
Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus.
Annelieke E C A B Willemsen et al.
International journal of cancer, 135(4), 1007-1007 (2014-01-15)
Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities.
Piguet AC, Majumder S, Maheshwari U, et al.
Clinical Science, 126(11), 775-784 (2014)
Enrique Fuentes-Mattei et al.
Journal of the National Cancer Institute, 106(7), doi:10-doi:10 (2014-06-25)
Obesity increases the risk of cancer death among postmenopausal women with estrogen receptor-positive (ER+) breast cancer, but the direct evidence for the mechanisms is lacking. The purpose of this study is to demonstrate direct evidence for the mechanisms mediating this...
Mikhail I Shtivelband
Breast (Edinburgh, Scotland), 22(4), 405-410 (2013-03-19)
Although patients with hormone receptor (HR)-positive breast cancer are successfully treated with endocrine therapy, many tumors go on to develop resistance to these agents. Studies have determined that mechanisms of resistance to endocrine therapy are quite complex and can involve...